Pharmafile Logo

Combination therapies in oncology: The benefits of integrated insights

14 June 2018
11am EDT | 8am PDT | 4pm BST | 5pm CE


In association with Pharmaceutical Executive

Register now: https://bit.ly/2L80Tme

Most experts believe combination therapies to be the future of oncology treatment. But with a number of new compounds approved and hundreds more in development, it’s difficult for many to identify which combinations and in what sequence, will form future treatment paradigms. In addition, the rising costs of newer agents and increased cost pressure creates an environment ripe for payer management.

In this webinar, pharma market research experts Anthony Greenwood, Dr Chris Gaj and  Brett Gardiner will look at the challenges and opportunities for effectively launching combination therapies across tumor types and, referencing their experience in oncology, demonstrate how integrated insights from payers, KOLs, community oncologists and patients can help support bio-pharma companies with oncology assets in all stages of clinical development.

Key Learning Objectives:

Delegates will:

  • Learn about the major themes, challenges and opportunities for marketing an oncology therapy in combination, including clinical trial design, pricing, sequencing and product attributes, amongst others
  • Understand implications of combining therapies from more than one manufacturer, anticipated pricing challenges and considerations for indication expansion
  • Understand the payer environment in oncology across the US and EU and uncover what evidence payers are looking for to make decisions about combination therapies
  • Understand how KOLs see oncology market evolving and how combination therapies will be utilized
  • Understand what effect patient characteristics may have on eventual treatment choice
  • Learn how integrated insights across all stakeholder groups can benefit launch strategies

Register now: https://bit.ly/2L80Tme

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

20 questions: Round 1

As it's our 20th year anniversary, we invited our employees to play 20 questions - this month "What's the biggest challenge you've overcome at Research Partnership?"Watch the video: https://www.researchpartnership.com/news/2017/03/20-questions-round-1/

Brand tracking research

A common challenge for brand tracking is ensuring the research programme stays relevant to the brand’s current environment. In this video Quantitative Research Directors Karen Swords and Vicky McLellan outline...

Pharma China Annual Forum 2017

We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.

Healthcare Market Research in the Gulf: 3 lessons I’ve learned

A few key considerations for conducting healthcare market research in the Gulf

Case study: Multiple Sclerosis new medical device research

Our client wanted to find out how best to develop an implantable delivery device technology with add-on services in the Multiple Sclerosis market. We were tasked with finding out whether such a...

Patient Centricity: Turning Rhetoric into Reality

Live webinar: Thursday 30th March 10:00 EDT / 15:00 BST / 16:00 CEST

Making sense of Nutraceuticals in China

Published in eyeforpharma February 2017 by Marc Yates

Research Partnership has been ranked in the Pharma Times Pharma Fast 50

Industry Magazine Pharma Times has partnered with Catalyst Corporate Finance to publish a detailed analysis of the 50 fastest growing private, independently owned pharma companies in the UK and Research...

Women’s health in emerging markets

Why can understanding and improving women’s health in emerging markets be challenging? What strategies can global pharma develop to support women and overcome these challenges? Associate Director Rachel Howard and...

Research Partnership has published a new Living with Lupus (SLE) market report for 2017

SLE is a progressive and debilitating disease which affects 5 million people worldwide.